Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Pet Cancer Therapeutics Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The pet cancer therapeutics market has experienced significant expansion in its size over recent years. It is projected to expand from $0.43 billion in 2025 to $0.48 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this expansion can be attributed to several factors: the rising incidence of cancer in companion animals, the development of conventional chemotherapy protocols, increasing veterinary hospital infrastructure, advancements in diagnostic imaging for pets, and the growth of the companion animal population.
The pet cancer therapeutics market is projected for substantial expansion in the coming years. Its valuation is forecast to reach $0.72 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.0%. This anticipated growth during the forecast period is fueled by several factors, including breakthroughs in immunotherapy and targeted therapies, the incorporation of artificial intelligence into diagnostic and treatment protocols, the widening reach of online and retail pharmacy outlets, greater understanding of the benefits of early cancer detection, and increased funding for veterinary oncology research. Key trends expected during this period involve the greater uptake of targeted therapies for pet cancer, the expanding application of immunotherapy in companion animals, the development of more comprehensive multi-modal cancer treatment approaches, an intensified emphasis on discovering pet cancer early, and the inclusion of palliative care within veterinary oncology practices.
Get A Free Sample Report With In-Depth Market Insights:
Pet Cancer Therapeutics Market Growth Factors: What’s Supporting Expansion?
The growing occurrence of pet cancer is anticipated to drive the expansion of the pet cancer therapeutics market in the future. Pet cancer refers to the development of abnormal and uncontrolled cell growth in the body of a domesticated animal, such as a dog or cat, leading to the formation of a tumor. The increased prevalence of pet cancer is mostly driven by exposure to environmental toxins and pollutants, along with genetic and lifestyle factors, which in turn is expected to boost the demand for more advanced and effective pet cancer therapeutics. These therapeutics help address pet cancer by targeting and destroying cancer cells or slowing tumor growth, thereby improving survival outcomes and reducing pain and discomfort in affected animals. For instance, in 2025, according to the American Veterinary Medical Association (AVMA), a US-based Veterinary Health Authority, approximately 1 in 4 dogs will develop cancer in their lifetime, and this risk grows to 1 in 2 for dogs aged over 10. Therefore, an increasing prevalence of pet cancer will fuel the pet cancer therapeutics market growth.
Pet Cancer Therapeutics Market Segmentation: How Does The Market Break Down By Category?
The pet cancer therapeutics market covered in this report is segmented –
1) By Cancer Type: Melanoma, Mast Cell Cancer, Lymphoma, Mammary And Squamous Cell Cancer
2) By Species: Dogs, Cats, Other Species
3) By Therapy: Chemotherapy, Radiation Therapy, Immunotherapy, Tomotherapy, Other Therapies
4) By End User: Veterinary Hospitals, Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, Other End Users
Subsegments:
1) By Melanoma: Surgical Interventions, Chemotherapy, Immunotherapy, Targeted Therapy
2) By Mast Cell Cancer: Surgery, Chemotherapy, Tyrosine Kinase Inhibitors, Radiation Therapy
3) By Lymphoma: Chemotherapy Protocols, Steroid Therapy, Radiation Therapy, Immunotherapy
4) By Mammary And Squamous Cell Cancer: Surgical Treatment, Chemotherapy, Radiation Therapy, Palliative Care Options
Pet Cancer Therapeutics Market Industry Trends: What’s Reshaping Demand?
Leading companies in the pet cancer therapeutics market are implementing technologies like epigenetic technology to enhance the efficacy and precision of targeting cancer cells, ultimately improving outcomes for pets with cancer. Epigenetic technology refers to approaches that modify gene expression without altering the underlying DNA sequence, frequently influencing cellular behavior and potential therapeutic results. For example, in April 2024, VolitionRx Limited, a US-based multi-national epigenetics firm, unveiled the Nu.Q Vet Cancer Test. The Nu.Q Vet Cancer Test functions on the Element i+ Analyzer, enabling fast results, typically within about 6 minutes. It utilizes an enzyme-linked immunosorbent assay to identify circulating nucleosomes in the blood, which can signify the presence of cancer.
Pet Cancer Therapeutics Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the pet cancer therapeutics market are AB Science, Elanco Animal Health, ELIAS Animal Health, Zoetis Inc., Anivive Lifesciences Inc., QBiotics Group Ltd., Regeneus Ltd., VetDC Inc., PetCure Oncology at Veterinary Radiosurgery and Imaging Center, Torigen Pharmaceuticals Inc., Dechra Pharmaceuticals plc, AdvaVet Inc., Oasmia Pharmaceuticals AB, Sumitomo Pharma Animal Health Co., Vetivax, CarthroniX Inc., Boehringer Ingelheim GmbH, Nippon Zenyaku Kogyo Co. Ltd., Vivesto AB, Norbrook Laboratories Ltd., Zenoaq Co. Ltd., Morphogenesis Inc.
View The Full Pet Cancer Therapeutics Market Report:
Pet Cancer Therapeutics Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the pet cancer therapeutics market in 2025. The regions covered in the pet cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
